Cite
HARVARD Citation
Tarride, J. et al. (2021). Hospitalization costs with degludec versus glargine U100 for patients with type 2 diabetes at high cardiovascular risk: Canadian costs applied to SAEs from a randomized outcomes trial. Journal of medical economics. pp. 1318-1326. [Online].